Overview of China's Market Approval Policy Med Insurance Payment System
Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.
In this whitepaper, hear from Parexel rare disease consultants on the following topics:
- Relevant Policies on Expedited Approval of Rare Disease Drugs
- An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs
Related Insights
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Related Insights
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026